1. [ 18 F]NaF PET/CT as a Marker for Fibrodysplasia Ossificans Progressiva: From Molecular Mechanisms to Clinical Applications in Bone Disorders.
- Author
-
Zwama, Jolien, Rosenberg, Neeltje M., Verheij, Vincent A., Raijmakers, Pieter G. H. M., Yaqub, Maqsood, Botman, Esmée, de Ruiter, Ruben D., Garrelfs, Mark R., Bökenkamp, Arend, Micha, Dimitra, Schwarte, Lothar A., Teunissen, Bernd P., Lammertsma, Adriaan A., Boellaard, Ronald, and Eekhoff, Elisabeth M. W.
- Subjects
FIBRODYSPLASIA ossificans progressiva ,POSITRON emission tomography ,COMPUTED tomography ,HETEROTOPIC ossification ,BONE diseases - Abstract
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic bone disorder characterized by episodic flare-ups in connective tissue, which are frequently followed by the formation of heterotopic ossification. The absence of available plasma-soluble biomarkers for flare-ups or heterotopic bone formation poses severe challenges to the monitoring of disease activity to measure or predict disease progression. Recently, 18-fluor-sodium fluoride positron emission tomography/computed tomography ([
18 F]NaF PET/CT) was introduced as a potential marker for ossifying FOP activity. This review discusses the pharmacokinetics of [18 F]NaF in relation to the pathophysiology of FOP, and its use as a marker of local bone metabolism in a variety of bone-related disorders. In addition, the review specifically addresses the applicability of [18 F]NaF PET/CT imaging in FOP as a monitoring modality. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF